Abstract. In both humans and animal models, diabetic sympathetic autonomic neuropathy is associated with the selective development of markedly enlarged distal axons and nerve terminals (neuroaxonal dystrophy, NAD). NAD occurs in the prevertebral superior mesenteric and celiac ganglia (SMG-CG), but not in the paravertebral superior cervical ganglion (SCG). To identify molecular differences between these ganglia that may explain their selective vulnerability to NAD, we have examined global gene expression patterns in control and diabetic rat sympathetic ganglia before and after the onset of structural evidence of NAD. As predicted, major differences in transcriptional profiles exist between SCG and SMG-CG in normal young adult animals including, but not limited to, known differences in neurotransmitter-related gene expression. Gene expression patterns of diabetic SMG-CG and SCG, prior to the development of NAD lesions, also differ from their age-matched non-diabetic counterparts. However, diabetes has ganglion-specific effects on gene expression; of approximately 110 transcripts that were differentially expressed between diabetic and control sympathetic ganglia, only 5 were differentially expressed as a result of diabetes in both SCG and SMG-CG. Genes involving synapse and mitochondrial structure and function, oxidative stress, and glycolysis were highly represented in the differentially expressed gene set. Differences in the number of synapserelated gene alterations in diabetic SMG-CG (18 genes) versus SCG (2 genes) prior to the onset of NAD may also well explain the selective development of NAD in the SMG-CG. These results provide support for the specificity of diabetesmodulated gene expression for selected neuronal subpopulations of sympathetic noradrenergic neurons.
INTRODUCTION
Diabetic autonomic neuropathy, a condition affecting the sympathetic and parasympathetic nervous systems, results in significant patient morbidity and substantially increased mortality (1) (2) (3) . The neuropathologic hallmark of diabetic sympathetic autonomic neuropathy is neuroaxonal dystrophy (NAD), a distinctive and unambiguous distal axonopathy resulting in markedly enlarged distal axons and nerve terminals (4) . Intraganglionic dystrophic axons are thought to represent aberrant intraganglionic sprouts that occur in the absence of significant neuron loss and are hypothesized to produce dysfunction and loss of ganglionic synapses. Rats with streptozotocin (STZ)-induced diabetes mellitus, like human diabetic patients, also develop pathologically distinctive degenerating, regenerating, and markedly swollen dystrophic axons and nerve terminals that are not accompanied by neuron or axon loss (5, 6) .
Examination of the postganglionic sympathetic axons projecting to a variety of endorgans in rats with chronic STZ-induced diabetes demonstrates that NAD develops most reproducibly in the distal segments of long noradrenergic axons innervating the intramural submucosal and myenteric ganglia of the ileum. Dystrophic changes do not develop in the equally lengthy nerves innervating arteries and veins within nearby neurovascular arcades (4) . The distinctive morphologic changes of NAD first become evident in rat superior mesenteric and celiac ganglia (SMG-CG) approximately 3 months after the onset of diabetes and fail to develop in the superior cervical ganglia (SCG), even in animals with diabetes of long duration (6) . It has been suggested that the differential development of NAD in nerves projecting to the ileum and those innervating neurovascular arcades reflects their origin from prevertebral and paravertebral sympathetic ganglia, respectively (4, 7, 8) . Consistent with this hypothesis, sympathetic ganglia are not equally affected by NAD in human diabetes (9) , with diabetic SMG-CG showing marked NAD and comparable changes being virtually absent in the SCG. Prevertebral and paravertebral sympathetic ganglia also differ in their response to aging (9, 10) , neonatal administration of NGF antisera or 6-hydroxydopamine (7, 11) , clonidine withdrawal (12) , speed of axonal regeneration after experimental injury (8) , and guanethidine sympathectomy (11) . These observations indicate that there are major differences between prevertebral and paravertebral sympathetic ganglia, some of which may predispose the prevertebral ganglia to the development of pathologies such as NAD.
Some of the distinctions between prevertebral and paravertebral sympathetic ganglia have been defined. Studies of the peripheral projections, neurotrophin sensitivity, and function of rat SCG demonstrate that this ganglion receives presynaptic inputs from the intermediolateral column of the spinal cord and then transmits signals to multiple postsynaptic targets. By comparison, prevertebral sympathetic ganglia have a more complex presynaptic input and a greater degree of neuronal heterogeneity (13, 14) . Analyses of the effects of surgical denervation and deafferentation and the expression of neurotransmitters, their synthetic enzymes, and a variety of neuropeptides indicate that prevertebral sympathetic ganglia are innervated by fibers projecting not only from the intermediolateral column of the spinal cord, but also from dorsal root ganglia, other sympathetic ganglia, the vagus nerve, and retrogradely from the intramural myenteric ganglia of the alimentary tract. Prevertebral sympathetic ganglia also contain nerve terminals representing intraganglionic projections from neighboring neurons, a source that may become particularly relevant in pathologic situations. Neurons within prevertebral sympathetic ganglia likewise differ from paravertebral chain ganglia in structural, functional, electrophysiologic and immunohistochemical characteristics (15) (16) (17) (18) (19) (20) . Therefore, the SCG acts more as a simple ''relay station,'' whereas prevertebral ganglia such as the SMG-CG appear to mediate the complex integration of a variety of visceral reflexes.
Despite improved understanding of the anatomy and function of prevertebral and paravertebral ganglia, the biochemical differences underlying their distinct function and the basis for the differences in their response to diabetes remain poorly understood. Furthermore, the molecular alterations that precede the development of NAD and the time course with which these alterations occur have not previously been investigated. Therefore, to better define molecular differences between sympathetic ganglia and their selective vulnerability to diabetes-induced NAD, we have used oligonucleotide microarrays to compare the transcriptomes of adult rat SCG and SMG-CG, both before and after the onset of STZ-induced diabetes. Data from this report demonstrates selective gene expression alterations in SCG and SMG-CG ganglia prior to onset of NAD, which may represent the molecular basis for the development of this neuropathology.
MATERIALS AND METHODS

Animals and Surgical Procedures
Male Sprague-Dawley rats (ϳ300 grams; Charles Rivers, Belmont, MA) received a single dose of STZ (65 mg/kg, i.v.; Upjohn, Kalamazoo, MI) in 0.01 M citrate/saline buffer (pH 4.5) and within a few days developed plasma glucose levels Ն350 mg% (mg/dl). Animals were housed and cared for in accordance within the guidelines of the National Institutes of Health and the Washington University Committee for the Humane Care of Laboratory Animals. Rats were killed 2, 6, or 17 weeks after the onset of diabetes. At each time point, right and left SCG, SMG, and CG from 11 to 12 diabetic rats were removed, cleaned of adherent tissue, and frozen on dry ice. For each time point, SCG from all animals were pooled together, as were SMG and CG. Ganglia from 11 to 12 control rats were similarly dissected, pooled, and frozen. The microarray data reported in this study reflect the results of 3 separate experiments (2 experiments performed at 2 weeks after the onset of diabetes and 1 performed 6 weeks after the onset of diabetes), each utilizing a pool of ganglia from 11 to 12 animals. Initial, independent analyses of microarray data from ganglia collected 2 and 6 weeks after the induction of diabetes showed that the transcriptional profile of each ganglion type was essentially identical at both of these time points. Therefore, for the purposes of this study analysis, we elected to treat all 3 experiments as identical ''prelesion diabetic'' time points.
High Density Oligonucleotide Microarray Hybridization and Scanning
Total RNA was isolated from ganglia using TRIzol reagent (Invitrogen, Carlsbad, CA) as recommended by the manufacturer. Double-stranded cDNA was synthesized from 20 g of total RNA using the SuperScript Choice System (Invitrogen) and an HPLC-purified oligo-dT primer containing an adjacent T7 RNA polymerase promoter (GENSET Corporation, La Jolla, CA). Biotinylated cRNA was transcribed from cDNA templates using an Enzo BioArray High Yield Transcript Labeling Kit (Affymetrix, Inc., Santa Clara, CA). Biotinylated cRNA was purified using RNeasy columns, fragmented and hybridized to rat genome U34A oligonucleotide arrays (Affymetrix) following the manufacturer's recommended protocol. After 16 hours hybridization, arrays were washed and stained with streptavidin-phycoerythrin. Hybridization signals were then amplified by labeling stained arrays with a biotinylated goat anti-streptavidin antibody (Vector Laboratories, Burlingame, CA) and restaining with streptavidin-phycoerythrin (Affymetrix EUK-GE-WS2 version 4 protocol). Arrays were scanned twice at 570 nm using an Affymetrix GeneArray scanner.
Analysis of Microarray Data
Microarray image data was analyzed using Affymetrix Microarray Analysis Suite 5.0 (MAS5). For each experiment, the MAS5 software was used to perform 3 relevant, binary array comparisons (i.e. control SCG vs control SMG-CG, control SCG vs diabetic SCG, control SMG-CG vs diabetic SMG-CG). The software output provided a statistical call regarding differential hybridization signal between the 2 arrays (''increase,'' ''decrease,'' ''no change'') and a calculated fold change in gene expression. For the purposes of this study analysis, only probe sets that showed a consistent ''increase'' or ''decrease'' in all 3 independent experiments were considered. The complete MIAME-compliant data set is available at http://bioinformatics. wustl.edu.
Real-Time Quantitative RT-PCR
Total RNA was isolated from ganglia using TRIzol reagent (Invitrogen) following the manufacturer's recommendations. One g of each total RNA was reverse transcribed in a 20-l reaction containing random hexamer primers and Moloney murine leukemia virus reverse transcriptase; a parallel reaction, performed identically except for the addition of reverse transcriptase, was used to verify an absence of genomic DNA contamination. After completion of reverse transcription, samples were diluted to 100 l with distilled water, boiled for 5 min and stored at Ϫ80ЊC until used in real-time PCR experiments.
Primers for real-time quantitative RT-PCR of ␤-actin and test mRNA were designed using Primer Express software (Version 2.0; Applied Biosystems, Inc., Foster City, CA) following the manufacturer's recommendations. Real-time PCR primers were designed from the following sequences: rat ␤-actin, GenBank accession # NM03144; rat prepronociceptin exon 2, GenBank accession # X97374; rat VGF, GenBank accession # M74223; rat chromogranin B, GenBank accession # AF019974; rat insulin-like growth factor I (IGF-I), GenBank accession # X06043. The sequences of the real-time PCR primers designed from these sequences are as follows:
␤-actin forward primer, TTCAACACCCCAGCCATGT ␤-actin reverse primer, GTGGTACGACCAGAGGCATACA Prepronociceptin forward primer, CCCTTATGTGTTTCAGCC TCTTG Prepronociceptin reverse primer, GCAGCAGGACATCACAA AACAG VGF forward primer, CCCGTTGGTCATGAAAACCT VGF reverse primer, CCCCCGGATGAGTAGAAGGA Chromogranin B forward primer, CCAGTGGATAACAGGGA TCACA Chromogranin B reverse primer, TAGGGCATTTGAGAGGA CTTCAA IGF I forward primer, GCCACGTCACCGCAAGAT IGF I reverse primer, TGGCAGGTGTTCCGATGTT
The relative abundance of each test transcript was determined using an ABI 5700 Gene Quantitation System (Applied Biosystems) and normalized to the levels of ␤-actin mRNA in the same specimen. Our microarray analyses showed no evidence of alterations in ␤-actin mRNA levels in diabetic SMG-CG or SCG. In addition, preliminary experiments in which we assayed ␤-actin mRNA levels in control and diabetic SMG-CG and SCG by real-time PCR and normalized these values to the levels of 18S ribosomal RNA in the same specimens showed no evidence of alterations in ␤-actin mRNA levels, indicating that it was an appropriate standard for normalization. Amplification of each specimen was performed in 6 replicates of a 25-l reaction containing 1 l of reverse transcription reaction and SYBR Green PCR Master Mix per the manufacturer's recommendations (Applied Biosystems). Preliminary experiments were performed to determine the optimal concentration of each forward and reverse primer and to verify that each primer set demonstrated similar amplification efficiencies under our reaction conditions. The relative quantity of each test mRNA was then established by normalizing the level of the corresponding cDNA to that of ␤-actin cDNA in the same reverse transcription reaction. Dissociation curves were performed after the completion of each PCR reaction to verify an absence of extraneous reaction products (e.g. primer-dimers) that might confound the quantitation of each target. Controls lacking added template were performed in parallel with each primer set to verify an absence of contamination.
RESULTS
Expression Profiling of Normal Rat SMG-CG and SCG Sympathetic Ganglia
To test the hypothesis that the differing response of prevertebral and paravertebral sympathetic ganglia to a variety of experimental and clinical insults reflects, in part, distinct transcriptional programs, we enumerated the transcriptome of normal SCG and SMG-CG in 3 independent experiments. We identified 141 unique transcripts that were consistently expressed at higher levels in SMG-CG relative to SCG, and 118 unique transcripts that were expressed at lower levels ( Table 1) . Most notably, we identified numerous differences in the expression of transcripts coding for specific neurotransmitters (e.g. somatostatin, prepronociceptin, and proenkephalin) and neurotransmitter receptors (e.g. tachykinin receptor 1, cholecystokinin A receptor, G protein-coupled receptor 51 [forms part of the GABA-B receptor], serotonin receptor and solute carrier family 6, member 4 [a serotonin transporter]). We also found major differences in expression of multiple genes encoding proteins necessary for synaptic structure and synaptic vesicle transport, fusion, and membrane recovery (e.g. synaptic vesicle glycoprotein 2b, synaptic cell adhesion molecule [similar to RA175 OC 363058], Arg/Abl-interacting protein ArgBP2). Given the cytoskeletal abnormalities evident in NAD, it was also notable that a large number of cytoskeletal protein transcripts (e.g. neurofilament heavy peptide, tubulin, peripherin, and actin) were expressed at substantially lower levels in SMG-CG relative to SCG. Thus, as predicted by anatomic and functional studies, major biochemical differences exist between these prevertebral and paravertebral sympathetic ganglia. Many of these differences involve transcripts encoding proteins whose function is likely affected during the development of NAD.
Identification of Genes with Altered Expression in Diabetic Sympathetic Ganglia
To identify genes whose expression is altered prior to the overt development of the morphologic lesions characteristic of NAD, rats were injected with a single dose of streptozotocin, a treatment that produced diabetes associated with markedly elevated plasma glucose levels ( Table 2 ). The expression profiles of diabetic SCG and SMG-CG were compared with those of control SCG and SMG-CG and consistent differences in all 3 experiments were identified (Table 3) . While we identified 82 transcripts with altered expression in diabetic SMG-CG, using the same criteria we identified a total of only 28 transcripts whose expression was changed in diabetic SCG. In pre-NAD, diabetic SMG-CG, we observed upregulation of transcripts encoding multiple neuropeptides (VGF nerve growth factor-inducible secreted protein, prepronociceptin) and neurotransmitter receptors (purinergic receptor P2X2, serotonin receptor). The expression of mRNA encoding proteins essential for synapse structure and function (N-ethylmaleimide sensitive factor (NSF), RAB 3A, RAB 11B, synapsin, chromogranin B, solute carrier family 18, membrane 1 [a chromaffin granule amine transporter], G PCR kinase-interactor 1) was typically increased in diabetic SMG-CG, although the expression of a number of transcripts was significantly decreased (monoamine oxidase A, B/K protein [synaptotagmin], annexin V, similar to MUM-2 protein). Increased expression of cytochrome P450 and diabetes-inducible P450RLM6 (which may eventually prove to be the same gene), as well as genes encoding enzymes essential for energy metabolism (particularly glycolysis, oxidative phosphorylation, and lipid metabolism) were also identified. On the other hand, diabetes was associated with a marked decrease in the expression of transcripts coding for mitochondrial uncoupling protein, as well as several other mitochondria-based enzymes. A transcript encoding galectin-related inter-fiber protein also demonstrated a striking and consistent 10-fold decrease in expression.
In contrast to SMG-CG, we identified very few changes in the transcriptome of diabetic SCG. For example, we identified only 2 synapse-related transcripts (similar to VAT-1, diazepam binding inhibitor) that were altered in diabetic SCG. Furthermore, diabetic SCG exhibited less prominent increases in transcripts encoding enzymes involved in glycolysis, oxidative phosphorylation, and lipid metabolism than were observed in prelesion diabetic SMG-CG.
Overall, diabetes-induced changes in gene expression were markedly different between sympathetic ganglia types. For example, expression of mRNA encoding tyrosine hydroxylase, a key enzyme in norepinephrine synthesis, is increased in diabetic rat SMG-CG but not in diabetic SCG, consistent with our previous studies indicating that the activity of this enzyme is selectively increased in diabetic SMG-CG (21) . In fact, of the 110 differentially expressed transcripts that were identified (82 in SMG-CG and 28 in SCG), only 5 demonstrated consistent changes in both types of diabetic ganglia (Table 3). These include mRNA for mitochondrial uncoupling protein (UCP-1), early growth response 1 (NGF-IA/Krox-24/EGR1), and cytochrome oxidase, all of which are substantially decreased in both ganglia, and ''upregulated by vitamin D1'' (Vdup1) and diabetes-inducible cytochrome P450RLM6, which are modestly increased in both ganglia.
Confirmation of Diabetes-Responsive Gene Expression
in Sympathetic Ganglia To validate the results of our microarray analyses and to further examine the expression of a set of transcripts potentially important in NAD pathogenesis, we quantitated the expression of selected mRNA in pre-lesion diabetic ganglia and ganglia with NAD. For these experiments, cDNA was prepared from RNA isolated from SMG-CG and SCG collected from rats 2 or 17 weeks after the injection of streptozotocin or vehicle. Real-time quantitative PCR was then used to assay the levels of mRNA-encoding neuropeptides (VGF, prepronociceptin), synaptic function (chromogranin B), or growth factors (IGF-I). The assayed levels of these messenger RNAs were normalized to the levels of ␤-actin mRNA in the same cDNA.
Using this approach, we found that each of the mRNAs whose expression was altered specifically in prelesion diabetic SMG-CG showed qualitatively similar changes by real-time PCR (Fig. 1) . We did note that the exact fold change determined by real-time quantitative PCR differed somewhat from the fold change determined in microarray experiments, a common finding in this type of comparison that has been described by several other laboratories. These alterations in mRNA expression persisted to 17 weeks after the induction of diabetes, a time well after the morphologic lesions of NAD have begun to appear. In contrast, none of these transcripts demonstrated mRNA levels that were significantly altered in diabetic SCG relative to SCG from vehicle-treated animals.
DISCUSSION
Comparison of the Gene Expression Profiles of SCG and SMG-CG in Control Rats
Neurons within normal prevertebral sympathetic ganglia differ from those in paravertebral chain ganglia in structural, functional, electrophysiologic, and immunohistochemical characteristics (15) (16) (17) (18) (19) (20) . Our systematic microarray analysis has also demonstrated marked differences in gene expression between pre-and paravertebral ganglia. Although we cannot exclude the possibility that some differentially expressed mRNA is expressed by other cell types within each ganglion (e.g. Schwann and satellite cells), it is likely that many of these transcripts are neuronally derived. The differences we have identified in the expression of somatostatin and prepronociceptin (both increased selectively in prevertebral ganglia) and the expression of serotonin receptors and transporters, calbindin, G protein-coupled receptor 51 [GABA-B receptor] and proenkephalin (all selectively increased in the SCG) parallel the results of immunohistochemical and in situ hybridization studies in rat and other species (16, (22) (23) (24) (25) (26) (27) (28) (29) and support the validity of our microarray analyses. Further, the substantially higher expression of mRNA-encoding tachykinin receptor 1 and cholecystokinin A receptor in SMG-CG compared to SCG is consistent with the known collateral projections of DRG and possibly vagal sensory axons as they pass through the prevertebral ganglia to visceral targets (13) (14) (15) .
The explanation that differences in neurotrophin support are responsible for the variation in ganglionic response between SCG and SMG-CG has been advanced (30) and disputed (31) . Our current studies are consistent with our previous immunohistochemical and in situ hybridization studies (31) demonstrating that trkA and p75 NTR dominate the neurotrophin receptor profile in both SMG-CG and SCG, far exceeding the expression of trkB and trkC. IGF-I gene expression is 2.8-fold higher in normal SMG-CG compared to the SCG, which suggests the possibility of autocrine or paracrine release of this important neurotrophic substance. Normal SMG-CG and SCG also differ markedly in expression of multiple genes encoding proteins involved in synaptic function or structure, including elements important in vesicle transport, fusion, and synaptic membrane recovery, which may underlie differences in the development of synaptic pathology and NAD.
Comparison of Diabetic and Control Rat Ganglia
Experimental and clinical diabetes differentially target the SMG-CG and SCG and their peripheral projections in human (9) and several experimental rodent models (6, 32) , including the STZ-diabetic rat. We found that diabetes alters the expression of multiple genes in both SCG and SMG-CG. Remarkably, only 5 genes of a combined total of 110 are increased in expression in both diabetic SMG-CG and diabetic SCG relative to their respective control ganglia. This degree of ganglionic specificity in diabetes-modulated gene expression is striking and unanticipated. STZ-diabetic rats develop NAD in postganglionic noradrenergic axons innervating the ileal intramural ganglia but not adjacent, equally lengthy noradrenergic axons innervating the mesenteric vasculature (4), which may reflect the origin of these axons from pre-and paravertebral ganglia, respectively (7, 8) . Selective involvement of the nitrergic innervation of the stomach of NOD mice (33) Locus Link ID (where available), gene description, and fold change of expression in the indicated diabetic ganglion are shown. Transcripts with similarly altered expression in both ganglia types are indicated in bold. Transcripts whose altered expression was confirmed by RT-PCR are indicated with an asterisk. For brevity, only representative known genes are displayed in this table. The full MIAME-compliant data set is available at http://bioinformatics.wustl.edu.
Fig. 1.
Real-time PCR validation of altered expression of selected transcripts in control, pre-lesion, and NAD diabetic superior mesenteric/celiac ganglia and superior cervical ganglia. Real-time quantitative RT-PCR was used to quantitate levels of insulin-like growth factor I (IGF-I), chromogranin B, prepronociceptin, and VGF nerve growth factor-inducible mRNAs in RNA isolated from pooled (8 to 24 ganglia per pool) superior mesenteric/celiac or superior cervical ganglia collected from rats injected with vehicle or streptozotocin after 2 weeks (''prelesion,'' A-D) or 17 weeks (''post-lesion,'' E-G). The levels of synapse-associated protein messenger RNA were normalized to the levels of ␤-actin mRNA measured in the same specimens. The normalized levels of each mRNA in normal superior mesenteric/celiac ganglia were used as a reference (1-fold), with the mRNA levels in all other ganglia calibrated relative to this standard (indicated by fold change on the vertical axis). Relative expression levels determined for each mRNA are represented by bars, with standard errors of the mean indicated for each bar.
response of established dissociated SCG and CG neuron cultures to a high glucose medium challenge in vitro (34) have also been reported. Our demonstration that diabetic SMG-CG and SCG develop distinct patterns of gene expression prior to the development of the morphologic lesions of NAD may provide a molecular underpinning for the differential development of this pathology. In light of the selectivity of NAD for the SMG-CG, it is notable that diabetes resulted in the altered expression of nearly 3-fold more transcripts in the SMG-CG than SCG. Further, the proteins encoded by these diabetes-responsive mRNAs mediate functions that provide important insights into the molecular mechanisms resulting in NAD.
Synaptic Structure/Function Genes NAD in the diabetic rat SMG-CG is a progressive, synapse-directed process requiring 3 or more months to develop as gauged by ultrastructural criteria. As NAD develops, dystrophic presynaptic axon terminals accumulate neurotransmitter granules, clathrin-coated vesicles, tubulovesicular elements, disorganized microtubules, and neurofilaments. In the SCG, which does not develop NAD, these abnormal accumulations are not evident. Synapse-directed processes, particularly those related to synaptic vesicle function, membrane retrieval, and turnover of subcellular organelles, are thus likely key targets during the pathogenesis of NAD.
We grouped genes involved in neurotransmitter synthesis and metabolism, receptor synthesis, and synapsedirected structural and functional elements into a single category for comparison. In the SMG-CG of diabetic animals, the expression of 18 genes encoding proteins involved in synaptic structure/function genes is altered. In contrast, only 2 genes showed minimally altered expression in the SCG from the same diabetic animals and these were different transcripts. Abnormalities affecting various nerve terminal constituents, particularly those involved in neurotransmitter release and recycling, are thought to play a role in the development of synaptic pathology in neurodegenerative diseases (35) . Our studies show diabetes likewise results in a ganglion-specific change in many synaptically directed genes. Increased expression of chromogranin B and solute carrier family 18, member 1 (chromaffin granule amine transporter) genes in diabetic SMG-CG may contribute directly to abnormal neurotransmitter granule number, structure, or function, perhaps providing a surplus of the enlarged, disorganized or neurotransmitter-deficient nerve terminal synaptic vesicles and their membranous aggregates prominent in NAD. Diabetes also results in the SMG-CG-specific altered expression of N-ethylmaleimide sensitive factor (NSF), secretogranin 2, B/K protein (synaptotagmin), annexin V, several Rabs (Rab 3A, Rab 11B), synapsin and purinergic receptor P2X, which are known to participate in synaptic vesicle transport, aggregation, docking, fusion, Ca ϩ2 dynamics, neurotransmitter release, and reuptake (36) (37) (38) (39) (40) (41) . Also increased is G PCR kinase interactor 1 protein, a molecule known to regulate ␤-2 adrenergic receptor endocytosis and, in excess, to hinder ␤2-adrenergic receptor signaling (42) . VGF, a secreted protein whose expression is increased more than 2-fold in diabetic SMG-CG (but not SCG) is an NGF-and BDNF-inducible gene product that is widely distributed in the CNS and PNS where it undergoes regulated release from dense core secretory vesicles (43) . VGF release is also regulated in vivo by electrical activity, injury, seizures, and feeding and its expression is modulated in association with circadian variation (44) , synaptic remodeling, and axonal sprouting (45) . Of particular relevance to diabetes, VGF plays a critical role in energy balance, with mice with a targeted deletion of this gene becoming hypermetabolic and demonstrating markedly reduced leptin levels and fat stores (46, 47) .
Mitochondria and Oxidative Stress
Oxidative stress in diabetic peripheral nerve (48) is thought to result from a variety of physiologic and pathophysiologic pathways (e.g. metabolism of nitric oxide, polyol pathway, arachidonic acid and catecholamines, leukocyte function, ischemia, formation of glycated proteins). Brownlee has proposed that a diabetes-induced increase in endothelial cell glucose metabolism produces an exaggerated proton gradient in mitochondria, resulting in the generation of excess ubiquinone intermediates and increased superoxide production (49), although others have reported an insulin-and NT-3-sensitive decrease in mitochondrial membrane potential in adult cultured DRG neurons (50) . Any of these processes may generate increased amounts of reactive oxygen species (ROS) in the sympathetic ganglia of diabetic animals, particularly in dystrophic nerve terminals, which may contain large aggregates of mitochondria (32) .
In the SMG-CG, diabetes alters the expression of numerous transcripts encoding mitochondrial proteins whose function is relevant to the metabolic alterations noted above. Particularly striking is a 20-to 30-fold decrease in the expression of uncoupling protein (UCP)-1, a protein initially identified on the basis of its thermogenic role (51) . Numerous recent studies have demonstrated that UCPs are also involved in ATP synthesis, control of the NADϩ/NADH ratio, weight regulation, control of fatty acid metabolism, and flux of lipid substrates across the mitochondrial membrane (52) , and, in particular, control of the generation of ROS. Overexpression of UCP in transgenic mice decreases the diabetesinduced proton gradient and normalizes deranged polyol, advanced glycosylation endproduct, protein kinase C, and hexosamine pathways (53) . Exposure to high glucose in vitro and in vivo also decreases expression of UCP-3, an event associated with increased generation of ROS (54) . Diabetes-induced reductions in ganglionic UCP-1 expression is thus likely to have multiple effects potentially contributing to NAD pathogenesis.
Of note, UCP-1 expression is decreased in both diabetic SCG and SMG-CG and so cannot by itself be responsible for selectivity of neuroaxonal dystrophy for SMG-CG. However, the expression of cytochrome P450, subfamily 2E (CYP2E1), which is present in both mitochondrial and microsomal intracellular compartments, is increased more than 10-fold in the diabetic SMG-CG but is unchanged in the SCG. Increased expression of mitochondrial CYP2E1 (55) has been proposed to increase ROS production in diabetic rat brain. Further, expression of diabetes-inducible cytochrome P450RLM6 (a gene product that is highly similar and may prove to be identical to the CYP2E1 protein identified in diabetic rat liver) is increased 1.8-fold in diabetic SCG and 3.6-fold in SMG-CG while expression of NADH cytochrome b5 reductase, a superoxide generator (56) is increased 40% in the SMG-CG but is decreased 30% in the SCG of the same animals. These alterations may interfere with respiratory chain function in diabetic ganglia, resulting in increased ROS production. Decreased expression of UCP-1 may worsen mitochondrial dysfunction and, in combination with the respiratory chain abnormalities occurring in SMG-CG, contribute to the pathogenesis of NAD.
Other Mechanisms
There are modest increases in the expression of transcripts encoding several enzymes in the glycolytic pathway, including hexokinase (1.6-fold), aldolase (1.3-fold: data not shown), and glyceraldehyde-3-phosphate dehydrogenase (1.3-fold: data not shown), of diabetic SMG-CG without comparable change in the SCG of the same animals. Increased glycolytic flux would be expected to increase mitochondrial activity, possibly resulting in an increase in ROS production, and increase activity in complication-related polyol, glucosamine, protein kinase C, and advanced glycosylation product pathways (49) .
The expression of the gene for galectin-related interfiber protein (GRIFIN), a key factor in injury-related axon growth (57, 58) , is 4.4-fold increased in normal rat SMG-CG compared to SCG, and responds to diabetes with a 10-fold decrease in expression in the SMG-CG in the absence of an effect on the SCG. Decreased GRIFIN expression in diabetic SMG-CG may interfere with terminal axon regeneration or collateral sprouting, thought to contribute to the pathogenesis of NAD (4). Galectin-3 upregulation in diabetic kidney protects against AGEinduced tissue injury (59) and a similar role in sympathetic ganglia could worsen AGE effects.
In summary, our analyses of the transcriptomes of the SMG-CG and SCG demonstrate that these ganglia express remarkably distinct profiles of mRNA, consistent with their distinct functions and differential susceptibility to the development of NAD. Our findings also indicate that the strikingly different responses of SMG-CG and SCG to diabetes occurs before the development of the morphologic lesions of NAD and involves genes encoding proteins mediating synaptic structure and function, mitochondrial function and responses to oxidative stress, glycolysis, and axon outgrowth. These observations suggest that alterations in one or more of these functions are important for the development of NAD. The genes we have identified in our studies should be highly useful markers for future investigations of the pathogenesis of this important diabetic autonomic neuropathy.
